| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
8-Bromo-2'-deoxyguanosine is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. It is also used as a starting structure for 2'-deoxyguanosine nucleotides modified at position 8.
|
|---|---|
| ln Vitro |
In vitro, 8-Bromo-2'-deoxyguanosine is used as a building block for nucleoside analogues employed in studying various ailments such as herpes, hepatitis B, and human immunodeficiency virus (HIV). Its unique chemical and biological properties make it a promising candidate for various applications in medical research.
|
| ln Vivo |
In vivo, 8-Bromo-2'-deoxyguanosine is not typically used as a therapeutic agent itself but serves as a key intermediate in the synthesis of antiviral nucleoside analogues.
|
| Enzyme Assay |
The compound is typically used as a chemical building block in organic synthesis. Its purity and identity are confirmed by standard analytical techniques such as NMR, HPLC, and mass spectrometry.
|
| Cell Assay |
8-Bromo-2'-deoxyguanosine is not typically used in cellular assays as a bioactive compound. Its primary use is as a synthetic intermediate.
|
| Animal Protocol |
8-Bromo-2'-deoxyguanosine is not used in animal studies as a pharmacological agent. Its applications are in medicinal chemistry and drug discovery.
|
| ADME/Pharmacokinetics |
8-Bromo-2'-deoxyguanosine has a molecular weight of 346.14 and is a solid at room temperature. It should be stored in a dark place, under inert atmosphere, at 2-8°C.
|
| Toxicity/Toxicokinetics |
8-Bromo-2'-deoxyguanosine is intended for research use only. Its toxicological profile would be evaluated in the context of the nucleoside analogues it helps to synthesize.
|
| References | |
| Additional Infomation |
8-Bromo-2'-deoxyguanosine is an organic bromine compound formed by the substitution of bromine at the 8-position of 2'-deoxyguanosine in the guanine ring system. It is an organic bromine compound belonging to the guanosine class of compounds.
8-Bromo-2'-deoxyguanosine is a halogenated purine nucleoside analog used as a key building block in the synthesis of antiviral and anticancer nucleoside analogues. It is useful as the starting structure for 2'-deoxyguanosine nucleotides modified at position 8. |
| Molecular Formula |
C10H12BRN5O4
|
|---|---|
| Molecular Weight |
346.14
|
| Exact Mass |
345.007
|
| CAS # |
13389-03-2
|
| PubChem CID |
135437126
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
2.5±0.1 g/cm3
|
| Boiling Point |
727ºC at 760 mmHg
|
| Melting Point |
>250ºC dec.
|
| Flash Point |
393.5ºC
|
| Vapour Pressure |
3.46E-22mmHg at 25°C
|
| Index of Refraction |
1.941
|
| LogP |
-0.02
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
20
|
| Complexity |
449
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
BrC1=NC2C(N([H])C(N([H])[H])=NC=2N1[C@]1([H])C([H])([H])[C@]([H])([C@]([H])(C([H])([H])O[H])O1)O[H])=O
|
| InChi Key |
MKDXZFVCXWXGBQ-VPENINKCSA-N
|
| InChi Code |
InChI=1S/C10H12BrN5O4/c11-9-13-6-7(14-10(12)15-8(6)19)16(9)5-1-3(18)4(2-17)20-5/h3-5,17-18H,1-2H2,(H3,12,14,15,19)/t3-,4+,5+/m0/s1
|
| Chemical Name |
2-amino-8-bromo-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8890 mL | 14.4450 mL | 28.8900 mL | |
| 5 mM | 0.5778 mL | 2.8890 mL | 5.7780 mL | |
| 10 mM | 0.2889 mL | 1.4445 mL | 2.8890 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
